Overview

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Status:
Active, not recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation